MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (HLA EPLETH DISPARITY AND IFN-γ ELISPOT) TO OPTIMIZE IMMUNOSUPPRESSIVE TREATMENT IN LIVING DONOR KIDNEY TRANSPLANT PATIENTS (BIOIMMUN)
This study is for people who have received a kidney transplant from a living donor. Doctors are trying to find the best way to give medicines that stop the body from rejecting the new kidney. They're doing this by using certain tests to understand each person's immune system better. The goal is to see if adjusting medicine doses based on these tests can lower the risk of problems like kidney damage or rejection, while also looking at side effects and other health issues over two years. It's a 'Phase IV' study, meaning the treatments are already approved and being studied to find the best way to use them.
At a glance
What is this study about?
When someone receives a new kidney from a living donor, their body's immune system naturally tries to fight it off, seeing it as something foreign. To stop this from happening, patients need to take special medicines called 'immunosuppressants'. These medicines reduce the immune system's activity, helping the body accept the new kidney. However, finding the perfect dose for each person is tricky, as too much medicine can lead to side effects, and too little can lead to the body rejecting the kidney.
This study, called BIOIMMUN, is looking into whether using specific blood tests can help doctors tailor these medications better for each patient. These tests check for certain 'markers' that show how active a person's immune system is against the new kidney. By understanding these markers, doctors hope to adjust the medicine doses more precisely, aiming to prevent rejection while also reducing side effects. They will be watching patients closely for two years to see if this personalised approach works better than standard treatment.
The main things the study wants to find out are if this tailored approach can reduce kidney damage, prevent the body from rejecting the kidney, and stop the development of certain 'antibodies' that can harm the transplant. They will also be looking at other important health aspects like infection rates, diabetes, heart problems, and even new cancers, as well as how well patients stick to their treatment plan.
Key takeaways
- This study aims to personalize kidney transplant treatment.
- It uses special tests to guide medication doses for living donor recipients.
- The goal is to prevent rejection and reduce side effects.
- Patients are followed for two years after their transplant.
- Participation involves regular check-ups and some additional tests.
Who may be eligible?
To be part of this study, you need to be at least 18 years old. There's no upper age limit, meaning older adults can also take part. The study is open to both men and women.
Crucially, you would need to have received a kidney transplant from a living donor. This study specifically focuses on patients undergoing this type of transplant to understand how to best manage their medications afterwards. If you received a kidney from a deceased donor, this particular study would not be suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you received a kidney transplant from a living donor?
- Are you able to attend regular appointments for two years?
- Are you willing to have extra blood tests and possibly kidney biopsies?
What does participation involve?
If you join this study, you will receive standard medications for a kidney transplant, which might include drugs like Prednisone, Simulect, Tacrolimus, Mycophenolate Mofetil, Methylprednisolone, or Thymoglobulin. What makes this study different is that your doctors will use special biomarker tests to help decide how much of these medications you receive, trying to find the best dose for you. You will have regular check-ups and assessments over two years. These appointments will involve blood tests to measure the biomarkers and check your kidney function and general health. You may also have kidney biopsies at 3 and 24 months to look closely at your kidney health. The total duration of your active involvement in the follow-up part of the study will be for two years.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What kind of medicines will I take?
You'll take standard medicines used after a kidney transplant to prevent rejection, like Prednisone and Tacrolimus. The study is about how doctors decide the best doses for you.
How long will I be involved in the study?
You'll be followed up for two years after your transplant, with regular check-ups and tests during this period.
Will I have more tests than usual?
Yes, you might have some extra blood tests to check specific markers and potentially kidney biopsies at 3 and 24 months to monitor your kidney's health very closely.
What is a 'biomarker'?
A biomarker is a substance in your body that doctors can measure, like in a blood test, to understand how your immune system is working.
What happens if I want to leave the study early?
You can leave the study at any time without having to give a reason. Your doctors will continue to look after you with standard care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.